Apixaban and Rilzabrutinib: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Aug 8, 2026 · Source data updated Jul 11, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Rilzabrutinib
Apixaban
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Here's what's going on. Rilzabrutinib (Wayrilz) can slow down a liver enzyme called CYP3A that helps clear apixaban (Eliquis) from your body. When that clean-up slows, more apixaban can build up. Since apixaban is a blood thinner, extra levels could raise your chance of bruising or bleeding.
The good news is that this is a theoretical concern based on how the drugs behave, not a proven problem. Your care team can manage it easily by watching you a little more closely and adjusting doses if needed. Please don't stop either medicine on your own. Just check in with your pharmacist or doctor so they can keep an eye on things.
Mechanism: Rilzabrutinib is a moderate CYP3A inhibitor. Apixaban is partially metabolized by CYP3A4 (and is a P-gp substrate), so coadministration is expected to increase apixaban exposure and bleeding risk. Neither drug is a prodrug, so the effect is additive to apixaban's anticoagulant activity.
- Direction: increased apixaban AUC/Cmax (increased drug effect).
- Magnitude: not quantified for apixaban; midazolam AUC rose up to 3.0-fold in ITP patients as a reference.
- Evidence: theoretical/predicted.
- Management: monitor for bleeding more frequently; consider individualized apixaban dose adjustment per the care team.
What happens
Increased CYP3A substrate exposure and an increased risk of CYP3A substrate-related adverse reactions
Interaction Deep Dive
When rilzabrutinib (a moderate CYP3A inhibitor) is given together with CYP3A substrates, exposure to those substrates may rise, raising the likelihood of adverse reactions tied to them. Watch more closely for adverse reactions caused by the co-administered CYP3A substrate and adjust its dosage as needed. A drug interaction study in healthy participants showed that giving a single 400 mg dose of rilzabrutinib alongside midazolam (a sensitive CYP3A substrate) raised midazolam Cmax and AUC by 2.2-fold. In patients with immune thrombocytopenia receiving 400 mg rilzabrutinib twice daily, midazolam AUC is projected to increase by as much as 3.0-fold1.
Why it happens (mechanism)
Inhibition of CYP3A-substrate metabolism by rilzabrutinib
How to manage this interaction
Keep taking both medications as prescribed unless your prescriber tells you otherwise. This interaction can usually be managed with a little extra attention.
- Your care team may monitor you more closely for signs of bleeding.
- Your apixaban dose may need to be adjusted and individualized by your care team.
- Watch for and promptly report unusual bruising, nosebleeds, pink or red urine, black or bloody stools, or bleeding that won't stop.
- Tell any new provider or pharmacist that you take both drugs so they can coordinate your care.
Management is individual — confirm any change with your pharmacist or prescriber.
Literature reports
1 report — tap to read
a) In a drug interaction trial involving healthy volunteers, taking a single 400 mg dose of rilzabrutinib together with midazolam (a sensitive CYP3A substrate) raised the Cmax and AUC of midazolam by 2.2-fold. In patients with immune thrombocytopenia, midazolam AUC is projected to rise as much as 3.0-fold when given alongside rilzabrutinib 400 mg twice daily 1.
Common questions
Can I take Apixaban and Rilzabrutinib together?
Rilzabrutinib may raise apixaban levels and bleeding risk, so watch for unusual bleeding or bruising and let your care team adjust the dose or monitoring as needed. Keep taking both unless your doctor says otherwise. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Apixaban and Rilzabrutinib interaction?
It is rated moderate. Can be significant — usually manageable with monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Apixaban and Rilzabrutinib interaction managed?
Keep taking both medications as prescribed unless your prescriber tells you otherwise. This interaction can usually be managed with a little extra attention. Your care team may monitor you more closely for signs of bleeding. Your apixaban dose may need to be adjusted and individualized by your care team. Watch for and promptly report unusual bruising, nosebleeds, pink or red urine, black or bloody… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
From our Q&A
Real reader questions about these medications, each personally answered by our pharmacist:
Questions for your pharmacist
- Does my dose of Apixaban or Rilzabrutinib need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there anything you'd monitor while I'm on both?
References (1)
- Product Information: WAYRILZ™ oral tablets, rilzabrutinib oral tablets. Genzyme Corporation (per FDA), Cambridge, MA, 2025. DailyMed
Keep reading about Rilzabrutinib
Keep reading about Apixaban
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist